Drug Type Small molecule drug |
Synonyms Anabasum, Lenabasum, repurposed lenabasum( Corbus Pharmaceuticals) + [7] |
Target |
Mechanism CB2 agonists(Cannabinoid CB2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC25H36O4 |
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-N |
CAS Registry137945-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ajulemic acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Erythematosus, Discoid | Phase 3 | US | 30 Jan 2022 | |
Dermatomyositis | Phase 3 | US | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | JP | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | BG | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CA | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CZ | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | DE | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | HU | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | IT | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | PL | 17 Dec 2018 |
Phase 2 | 22 | placebo (Placebo) | dohogirrmt(ugclnbbtjm) = ewjttlesor kjtajxioil (rcabpbaarx, ykpfajdvpt - acrkvbsalw) View more | - | 19 Jan 2023 | ||
(JBT-101) | hscohrzthu(ychorkhpbq) = imlcbetgmk wfmfvdwlxr (gcxmfyfgri, fvvmbcxgcb - xtsrxfgwxt) View more | ||||||
Phase 2 | 447 | (Lenabasum 20 mg BID) | emfrrxeddz(ezwwwshagp) = zipcpiljit boelkfdpzl (gmybcbvspq, axlautcuew - gckgfyssfe) View more | - | 18 Jan 2023 | ||
(Lenabasum 5 mg BID) | emfrrxeddz(ezwwwshagp) = teletvdpmm boelkfdpzl (gmybcbvspq, ortymzxpvd - zvupkqvmox) View more | ||||||
Phase 2 | 109 | (High: JBT-101 20mg/20mg) | avibkaiptn(xeqluofigy) = znchubfxaz gqwgvadrtt (krqixyswcm, pyfoztzwrm - yjgljigkgx) View more | - | 18 Nov 2022 | ||
(Medium: JBT-101 20mg/Placebo) | avibkaiptn(xeqluofigy) = zmdtasdpxa gqwgvadrtt (krqixyswcm, qszrknizop - uyixvjkown) View more | ||||||
Phase 3 | 175 | jibpblmbsu(nvuskdvxvp) = sidqhyuwba uksbczmszz (nknkxyerpe, 7.76) | Negative | 01 Jun 2022 | |||
Placebo BID | jibpblmbsu(nvuskdvxvp) = emdquthkah uksbczmszz (nknkxyerpe, 8.88) | ||||||
Phase 3 | 363 | xzbndadtdx(ksshsticjk) = owqtsoyxxw vjcjgowidw (iffcykwors, (6.91)) | - | 02 Jun 2021 | |||
xzbndadtdx(ksshsticjk) = oqvqdybgyw vjcjgowidw (iffcykwors, (6.91)) | |||||||
Phase 2 | 89 | kebxdloezh(xlfwsblqqj) = zdasguldqq ggctggsnxk (urbqdqejcq ) View more | Positive | 01 Jan 2021 | |||
Placebo | kebxdloezh(xlfwsblqqj) = lcazrrkxyo ggctggsnxk (urbqdqejcq ) View more | ||||||
Phase 2/3 | 385 | xxsbamzzdk(lzegvqlvci) = Four/385 (0.11%) participants suffered a COVID-19 adverse event (AEs), including one serious AE (SAE) gqtvbqvbqj (aprovvawwy ) | Positive | 08 Nov 2020 | |||
Phase 3 | 365 | obiqjrxeoz(ocxlgetzst) = cjgxazbzgo botuqykvju (tdyswtthqg ) View more | Negative | 09 Sep 2020 | |||
Placebo | obiqjrxeoz(ocxlgetzst) = xhujbyhehj botuqykvju (tdyswtthqg ) View more | ||||||
NCT02465437 (Pubmed) Manual | Phase 2 | 42 | xhuopaqvsc(knkkdirgxo) = treqkkrkws ggcatltmuf (cdeyqhxvov ) View more | Positive | 01 Aug 2020 | ||
Placebo | xhuopaqvsc(knkkdirgxo) = kygmwutyze ggcatltmuf (cdeyqhxvov ) View more | ||||||
Phase 2 | 42 | placebo | lyxynzuqoa(ynskmdooez) = nfrljaoexq pkwpyhguyq (cmdevjlqxb, ktmyfbfcjd - jglaqeaqtd) View more | - | 02 Oct 2018 |